Spatial Heterogeneity of PD‐L1 Expression as a Biomarker for Third‐Generation EGFR‐TKI Response in Advanced EGFR‐Mutant NSCLC

Documenti analoghi

• Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
  di: Leah Lawrence
  Pubblicazione: (2026)
• Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC
  di: Yuxiang Sun, et al.
  Pubblicazione: (2026)
• Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and Challenges
  di: Xuexue Zhou, et al.
  Pubblicazione: (2025)
• More treatment options emerge for EGFR ‐mutant NSCLC
  di: Leah Lawrence
  Pubblicazione: (2026)
• Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
  di: Kei Sonehara, et al.
  Pubblicazione: (2024)